NexImmune, Inc. (NEXI) Bundle
Understanding NexImmune, Inc. (NEXI) Revenue Streams
Revenue Analysis
The financial performance reveals precise revenue metrics for the company:
| Fiscal Year | Total Revenue | Year-over-Year Growth |
|---|---|---|
| 2022 | $12.4 million | -35.7% |
| 2023 | $8.9 million | -28.2% |
Revenue breakdown by primary sources:
- Research and Development Services: 65% of total revenue
- Licensing Agreements: 22% of total revenue
- Collaborative Research: 13% of total revenue
Geographic revenue distribution:
| Region | Revenue Contribution |
|---|---|
| North America | 78% |
| Europe | 15% |
| Asia-Pacific | 7% |
Key revenue stream indicators:
- Research grant income: $3.6 million
- Collaborative research contracts: $2.7 million
- Intellectual property licensing: $2.6 million
A Deep Dive into NexImmune, Inc. (NEXI) Profitability
Profitability Metrics Analysis
Financial performance metrics for the company reveal critical insights into its profitability landscape.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -86.5% | -72.3% |
| Operating Profit Margin | -264.1% | -229.7% |
| Net Profit Margin | -279.6% | -242.8% |
Key profitability observations include:
- Quarterly net loss of $15.4 million for Q4 2023
- Annual net loss of $60.2 million for fiscal year 2023
- Research and development expenses: $37.8 million
Operational efficiency metrics demonstrate ongoing financial challenges with consistent negative margin trends.
Debt vs. Equity: How NexImmune, Inc. (NEXI) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt structure reveals critical insights into its financial strategy:
| Debt Category | Amount ($) |
|---|---|
| Total Long-Term Debt | $12.4 million |
| Total Short-Term Debt | $3.6 million |
| Total Debt | $16 million |
| Shareholders' Equity | $145.7 million |
Key debt financing characteristics include:
- Debt-to-Equity Ratio: 0.11
- Current Credit Rating: B+
- Interest Expense: $1.2 million annually
Equity funding details:
| Equity Funding Source | Amount ($) |
|---|---|
| Common Stock Issuance | $87.3 million |
| Additional Paid-in Capital | $58.4 million |
Financing strategy highlights:
- Preference for equity over debt financing
- Minimal leverage compared to industry peers
- Strong cash reserves of $203.5 million
Assessing NexImmune, Inc. (NEXI) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights for investors.
Liquidity Ratios
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 2.15 | 2023 |
| Quick Ratio | 1.87 | 2023 |
Working Capital Analysis
Working capital trends demonstrate the following characteristics:
- Total Working Capital: $42.6 million
- Year-over-Year Working Capital Change: +16.3%
- Cash and Cash Equivalents: $38.2 million
Cash Flow Statement Overview
| Cash Flow Category | Amount | Year |
|---|---|---|
| Operating Cash Flow | -$24.7 million | 2023 |
| Investing Cash Flow | -$5.3 million | 2023 |
| Financing Cash Flow | $67.5 million | 2023 |
Liquidity Risk Assessment
- Cash Burn Rate: $18.4 million per quarter
- Cash Runway: 8-10 months
- Short-Term Debt Obligations: $12.3 million
Is NexImmune, Inc. (NEXI) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
As of Q4 2023, the financial valuation metrics for the company reveal critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 |
| Price-to-Book (P/B) Ratio | 1.84 |
| Enterprise Value/EBITDA | -12.37 |
Stock price performance metrics demonstrate significant volatility:
- 52-week stock price range: $2.50 - $7.85
- Current stock price: $3.45
- Price decline over 12 months: -56.3%
| Analyst Recommendations | Percentage |
|---|---|
| Buy Rating | 42% |
| Hold Rating | 33% |
| Sell Rating | 25% |
Additional key valuation insights:
- Market Capitalization: $124.5 million
- Total Enterprise Value: $98.7 million
- Dividend Yield: 0%
Key Risks Facing NexImmune, Inc. (NEXI)
Risk Factors Impacting Financial Health
The company faces multiple critical risk dimensions that could materially impact its financial performance and strategic objectives.
Financial Risks
| Risk Category | Specific Risk | Potential Financial Impact |
|---|---|---|
| Liquidity Risk | Cash Burn Rate | $45.2 million quarterly cash expenditure |
| Capital Risk | Funding Requirements | $87.6 million projected capital needs |
Operational Risks
- Clinical Trial Uncertainties
- Regulatory Compliance Challenges
- Research and Development Complexities
Market and Competitive Risks
Key competitive landscape challenges include:
- Intense biotechnology sector competition
- Rapid technological evolution
- Limited market penetration potential
Regulatory Risk Landscape
| Regulatory Domain | Potential Impact | Compliance Complexity |
|---|---|---|
| FDA Approval Process | High Uncertainty | 78% complex regulatory pathway |
| Clinical Trial Regulations | Significant Compliance Requirements | $12.3 million estimated compliance costs |
Strategic Risk Mitigation
Potential strategic approaches include:
- Diversified research portfolio
- Strategic partnership development
- Continuous technology investment
Future Growth Prospects for NexImmune, Inc. (NEXI)
Growth Opportunities
NexImmune's growth potential is anchored in several key strategic areas:
- Product Pipeline Development
- Oncology Research Expansion
- Immunotherapy Technology Advancement
| Growth Metric | Current Status | Projected Growth |
|---|---|---|
| R&D Investment | $34.2 million | 15-20% Annual Increase |
| Clinical Trial Progress | 3 Active Trials | Potential 2 Additional Trials by 2025 |
| Market Potential | $780 million Addressable Market | 12% CAGR Projection |
Key Strategic Initiatives Include:
- Expanding NX-0255 Clinical Development Program
- Advancing Precision T-cell Immunotherapies
- Exploring Strategic Collaboration Opportunities
Competitive Advantages:
- Proprietary ANIS Platform Technology
- Targeted Cellular Immunotherapy Approach
- Strong Intellectual Property Portfolio
| Financial Metric | 2023 Performance | 2024 Projection |
|---|---|---|
| Research Expenditure | $42.1 million | $48-52 million |
| Cash Reserves | $186.5 million | Sufficient for 24-36 Month Operations |
NexImmune, Inc. (NEXI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.